FCARH143

FCARH143 is an autologous chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), developed for the treatment of relapsed or refractory multiple myeloma. The product is manufactured from a patient’s own (autologous) CD4 and CD8 T cells collected via leukapheresis. These subsets are selected and separately transduced with a lentiviral vector encoding a fully human single-chain variable fragment (scFv) specific for human BCMA and incorporating a 4-1BB costimulatory domain. The modified cells are then expanded and formulated in a 1:1 ratio of CD4 to CD8 CAR-T cells before cryopreservation and administration[1][3][4]. Upon infusion, these engineered CAR-T cells recognize and bind to the BCMA protein on malignant plasma cells in multiple myeloma, inducing selective cytotoxicity through immunologic mechanisms[2]. Clinical studies have shown potent anti-myeloma activity with high response rates in heavily pretreated patients; however, development has been limited by issues such as relapse due to low or lost BCMA expression on tumor cells. Combination strategies using gamma-secretase inhibitors like crenigacestat have been explored to increase surface density of BCMA on target myeloma cells prior to infusion[3][5]. Development was led by Fred Hutchinson Cancer Research Center in collaboration with Juno Therapeutics/Bristol Myers Squibb.

Other names

Autologous anti-BCMA-CAR-expressing CD4+/CD8+ T lymphocytes FCARH143BCMA CAR-CD4+/CD8+ T cellsBCMA-specific CAR-expressing CD4+/CD8+ T lymphocytes